stockrow
Saturday 7 November 2026
Export PGNY’s income statement to Excel — free account
Progyny, Inc.
PGNY Healthcare Healthcare Plans
Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +8.91%
- EPS
- +115.3%
- Free cash flow
- +2.72%
Quarter to September 2026, against a year earlier
34.84
0.47
+1.37%
Follow PGNY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.82 | 29.72 | 20.96 | 37.22 |
+8 more quarters Free account |
P/S ratio |
1.43 | 1.72 | 1.06 | 1.71 | |
P/FCF ratio |
10.69 | 12.63 | 7.45 | 11.47 | |
P/Operating CF |
33.92 | 44.69 | 29.90 | 40.58 | |
P/B ratio |
4.64 | 4.97 | 3.13 | 4.26 | |
Price to Tangible BV |
4.94 | 5.27 | 3.32 | 4.49 | |
EV/Sales |
1.29 | 1.54 | 0.89 | 1.47 | |
EV/EBITDA |
14.67 | 17.15 | 11.33 | 20.99 | |
EV/Operating CF |
8.35 | 10.04 | 5.59 | 9.01 | |
EV/FCF |
9.63 | 11.33 | 6.26 | 9.88 | |
Quick Ratio |
1.85 | 2.06 | 2.07 | 2.62 | |
Current Ratio |
1.93 | 2.14 | 2.13 | 2.73 | |
Net Debt/EBITDA |
0.00 | (5.69) | (6.11) | (18.22) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.82 | 1.78 | 1.81 | 1.91 | |
Operating CF/Net income |
2.16 | 1.80 | 1.90 | 4.34 | |
Capex/Depreciation |
(4.35) | (3.83) | (4.28) | (3.12) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
14.23% | 14.06% | 14.52% | 19.37% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
6.18% | 5.84% | 6.00% | 10.93% | |
Graham Net Nets |
0.11 | 0.11 | 0.18 | 0.15 | |
Graham Number |
11.88 | 11.25 | 9.95 | 9.67 | |
Earnings Yield |
4.58% | 3.36% | 4.77% | 2.69% | |
Free Cash Flow Yield |
9.36% | 7.92% | 13.42% | 8.72% | |
Revenue per Share |
4.48 | 4.48 | 4.06 | 3.72 | |
Operating CF per Share |
0.74 | 0.65 | 0.57 | 0.63 | |
Capex per Share |
(0.12) | (0.08) | (0.08) | (0.07) | |
Free Cash Flow per Share |
0.62 | 0.57 | 0.49 | 0.57 | |
Cash per Share |
2.57 | 3.03 | 2.78 | 3.62 | |
Shareholders Equity per Share |
5.43 | 5.80 | 5.43 | 6.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.43 | 5.80 | 5.43 | 6.02 | |
Free Cash Flow |
47.24 | 44.21 | 39.60 | 48.59 | |
Working Capital |
224.36 | 272.93 | 265.81 | 349.38 | |
Capital Expenditures |
(9.36) | (6.22) | (6.35) | (5.61) | |
Net Current Asset Value |
202.64 | 250.44 | 242.56 | 325.38 | |
EV/EBIT |
13.75 | 18.03 | 11.96 | 22.21 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
15.27 | 20.10 | 14.24 | 25.79 | |
| Other line items | |||||
Average Receivables |
250.84 | 264.66 | 281.68 | 227.81 | |
Average Payables |
135.55 | 146.28 | 151.77 | 109.58 | |
Average Assets |
735.51 | 738.39 | 714.31 | 674.77 | |
Average Common Equity |
487.02 | 484.14 | 453.25 | 469.05 |
Columns are period end dates · fundamentals updated 6 Nov 2026